Diabetes Drug Metformin Combined with Exercise Has Surprise Effect on Glucose Control

August 22nd, 2011

It's common enough for researchers to look at the impacts of prescribed drugs on the body. And if you're a diabetes researcher who believes that exercise has great benefits for those with type 2 diabetes, you're hoping your research will show that. But when Normand Boulé looked at the dual impacts of exercise and metformin - two of the most commonly-prescribed modalities for glucose control -the hoped-for double whammy wasn't the result.

Researchers looking at the effects of the oral diabetes medication metformin and exercise in Type 2 diabetes patients found that a combination of these modalities didn't lower glucose control as much as hoped. Surprisingly, study participants showed better glucose control when sedentary. Researchers think that because prescription metformin and exercise both act to lower glucose levels, the combination may have triggered a counter regulatory response by the body to prevent glucose levels dipping too much.

Read the full article on ScienceDaily-

Chewable Oral Diabetes Medication Enters Clinical Testing

October 12th, 2011

diabetes medication

Boston Therapeutics, Inc., a developer of diabetes therapeutics, announced the initiation of its first clinical trial of its investigational diabetes medication, PAZ320, when added to other oral diabetes medication or insulin injections in patients with type 2 diabetes. Boston Therapeutics is a leader in the specialized field of glyco-pathology, focused on understanding the importance of carbohydrates in biochemistry and the progression of diseases.

"We have already seen significant reduction of post-meal elevation of glucose in preclinical models with PAZ320," said David Platt, Ph.D., Chief Executive Officer of Boston Therapeutics. "We are excited about our collaboration with endocrinologist Dr. Sushela Chaidarun, PhD. and Dr. Laura E. Trask at Dartmouth Hitchcock Medical Center, and the possibility to help millions of people with high blood sugar and diabetes."

PAZ320 is a chewable complex carbohydrate-based compound designed to reduce the post-meal elevation of blood glucose. A proprietary polysaccharide designed to be taken before meals, it works in the gastrointestinal system, blocking the action of the carbohydrate-hydrolyzing enzymes that break carbohydrates down into glucose and release it into the bloodstream.

This clinical study will evaluate the safety and efficacy of PAZ320 when added to oral diabetes medications or insulin injections. The study population will consist of adults aged 18-75 years with type 2 diabetes, either on oral agents or insulin with a BMI of 25-35 kg/m2 and with A1c of less than 9.0%. The study will be conducted at Dartmouth-Hitchcock Medical Center in New Hampshire - one of America's oldest and most respected medical schools

"Given the many complications that stem from uncontrolled diabetes, it is important to implement measures that will better control glucose levels throughout the day," said Dr. Trask, Co-Principal Investigator of the study, along with Dr. Chaidarun. "By providing another way to appropriately control the postprandial glucose increase following a meal, diabetics may better control their glucose level."

Boston Therapeutics has also developed SUGARDOWN, a chewable complex carbohydrate-based dietary supplement that is taken before carbohydrate-containing meals to reduce the absorption of glucose from the intestinal tract and moderate post-meal blood glucose.